Fisher Asset Management LLC Acquires New Position in Kura Oncology, Inc. $KURA

Fisher Asset Management LLC acquired a new stake in Kura Oncology, Inc. (NASDAQ:KURA) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 471,993 shares of the company’s stock, valued at approximately $4,904,000. Fisher Asset Management LLC owned 0.54% of Kura Oncology as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Nan Fung Trinity HK Ltd. purchased a new position in Kura Oncology during the 3rd quarter valued at about $2,043,000. SG Americas Securities LLC grew its holdings in Kura Oncology by 214.1% during the 4th quarter. SG Americas Securities LLC now owns 151,715 shares of the company’s stock valued at $1,576,000 after buying an additional 103,411 shares in the last quarter. UBS Group AG grew its holdings in Kura Oncology by 118.3% during the 4th quarter. UBS Group AG now owns 1,060,025 shares of the company’s stock valued at $11,014,000 after buying an additional 574,455 shares in the last quarter. Rhenman & Partners Asset Management AB grew its holdings in Kura Oncology by 96.0% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 490,000 shares of the company’s stock valued at $4,336,000 after buying an additional 240,000 shares in the last quarter. Finally, Moody Aldrich Partners LLC purchased a new position in Kura Oncology during the 4th quarter valued at about $1,867,000.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on KURA. Zacks Research raised Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Thursday, February 26th. Jefferies Financial Group set a $24.00 target price on Kura Oncology in a report on Thursday. UBS Group reaffirmed a “buy” rating and set a $15.00 target price (down from $16.00) on shares of Kura Oncology in a report on Friday, March 13th. Mizuho reduced their target price on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, March 24th. Finally, Lake Street Capital started coverage on Kura Oncology in a report on Tuesday, April 14th. They set a “buy” rating and a $23.00 price objective for the company. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.90.

Kura Oncology Stock Down 2.6%

Shares of NASDAQ KURA opened at $9.97 on Friday. Kura Oncology, Inc. has a 12 month low of $5.45 and a 12 month high of $12.49. The company has a current ratio of 6.15, a quick ratio of 6.14 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $885.04 million, a price-to-earnings ratio of -2.98 and a beta of 0.32. The business has a 50-day moving average of $9.15 and a 200-day moving average of $9.47.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The company had revenue of $18.27 million during the quarter, compared to analyst estimates of $25.97 million. Sell-side analysts expect that Kura Oncology, Inc. will post -3.51 earnings per share for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.